National Guideline Clearinghouse | Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline, version 3.

full-text ►

National Guideline Clearinghouse | Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline, version 3.



Program in Evidence-based Care

 Cancer Care Ontario Web site

Guideline Title

Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline, version 3.

Bibliographic Source(s)

Prica A, Baldassarre F, Hicks LK, Imrie K, Kouroukis TC, Cheung M. Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline, version 3. Toronto (ON): Cancer Care Ontario (CCO); 2015 Mar 31. 173 p. (Evidence-based series; no. 6-8).  [236 references]

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Imrie K, Stevens A, Meyer R, Hematology Disease Site Group. Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Dec 22. 46 p. (Evidence-based series; no. 6-8). [65 references]

The EVIDENCE-BASED SERIES report, initially the full original guideline, over time will expand to contain new information emerging from their reviewing and updating activities.

Please visit the Cancer Care Ontario Web site  for details on any new evidence that has emerged and implications to the guidelines.

This guideline meets NGC's 2013 (revised) inclusion criteria.